BioLife Solutions Inc. Common Stock (BLFS)
Stock · NASDAQ · Health Care
$38.61as of 10/7/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
BLFS Signal Track Record
How signals performed across all stocks →What BLFS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +3.0% | 68% | October 2, 2026 |
| Bollinger Band Breakout | 26 | +6.2% | 65% | September 22, 2026 |
| 200-Day Moving Average Touch | 22 | -3.1% | 45% | May 20, 2026 |
| Bollinger Band Breakdown | 21 | +4.7% | 67% | March 3, 2026 |
| Any 20-session window (baseline) | +1.6% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 155
- Website
- www.biolifesolutions.com/
Fundamentals
- 1-day range
- $36.96$38.83
- Market cap
- $1.66B
- P/E (trailing)
- 32.58
- P/E (forward)
- 117.00
- EPS (trailing)
- $1.18
- Dividend yield
- —
- Beta
- 1.73
- Avg. volume
- 1.15M
How BioLife Solutions Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
BioLife Solutions Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BLFSBioLife Solutions Inc. Common Stock$38.61▲ 0.00%Market cap $1.66BP/E 32.58$17.86$39.76
- CNMDCONMED Corporation Common Stock$46.72▼ 0.89%Market cap $1.49BP/E 25.13$31.44$53.66
- INMDInMode Ltd. Ordinary Shares$14.16▼ 1.12%Market cap $957.98MP/E 10.66$12.72$16.67
- AXGNAxogen Inc. Common Stock$34.62▼ 2.83%Market cap $2.38BP/E —$15.27$52.91
- CBLLCeriBell Inc. Common Stock$25.04▼ 9.41%Market cap $692.45MP/E —$10.85$26.63
- TMDXTransMedics Group Inc. Common Stock$70.78▼ 7.50%Market cap $2.78BP/E 17.33$60.11$156
- CVCapsoVision Inc. Common Stock$6.53▲ 1.24%Market cap $344.75MP/E —$4.46$15.37
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BLFS BioLife Solutions Inc. Common Stock | $1.66B | 32.58 | $38.61 | ▲ 0.00% | $17.86$39.76 |
| CNMD CONMED Corporation Common Stock | $1.49B | 25.13 | $46.72 | ▼ 0.89% | $31.44$53.66 |
| INMD InMode Ltd. Ordinary Shares | $957.98M | 10.66 | $14.16 | ▼ 1.12% | $12.72$16.67 |
| AXGN Axogen Inc. Common Stock | $2.38B | — | $34.62 | ▼ 2.83% | $15.27$52.91 |
| CBLL CeriBell Inc. Common Stock | $692.45M | — | $25.04 | ▼ 9.41% | $10.85$26.63 |
| TMDX TransMedics Group Inc. Common Stock | $2.78B | 17.33 | $70.78 | ▼ 7.50% | $60.11$156 |
| CV CapsoVision Inc. Common Stock | $344.75M | — | $6.53 | ▲ 1.24% | $4.46$15.37 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Freshworks Stock Bumped Higher TodayYahoo · 10/6/2026
- Why Are Freshworks (FRSH) Shares Soaring TodayYahoo · 10/6/2026
- Repligen Completes Acquisition of BioLife SolutionsYahoo · 10/6/2026
- Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On TuesdayBenzinga · 10/6/2026
- Freshworks Set to Join S&P SmallCap 600Yahoo · 10/5/2026
- Freshworks stock climbs on S&P SmallCap 600 inclusionYahoo · 10/5/2026
- Freshworks Set to Join S&P SmallCap 600; Will Replace BioLife Solutions On October 8Benzinga · 10/5/2026
- BioLife Solutions Shareholders Approve Repligen Merger AgreementYahoo · 10/5/2026
Insider Activity
Insider Actions →- Werner Sean · October 6, 2026 · Disposition70.0K
- Werner Sean · October 6, 2026 · Tax Withholding71.2K @ $38.61
- Werner Sean · October 6, 2026 · Grant48.2K
- Werner Sean · October 6, 2026 · Grant45.8K
- Wichterman Troy · October 6, 2026 · Disposition256.0K
- Wichterman Troy · October 6, 2026 · Tax Withholding95.9K @ $38.61
- Wichterman Troy · October 6, 2026 · Grant62.3K
- Wichterman Troy · October 6, 2026 · Grant76.2K
- DuRoss Amy · October 6, 2026 · Disposition26.9K
- Coste Catherine · October 6, 2026 · Disposition13.9K
- Timothy L. Moore · October 6, 2026 · Disposition44.9K
- Berard Todd · October 6, 2026 · Disposition194.8K
- Berard Todd · October 6, 2026 · Tax Withholding46.2K @ $38.61
- Berard Todd · October 6, 2026 · Grant40.2K
- Berard Todd · October 6, 2026 · Grant38.2K
Institutional Ownership
March 31, 2026
- Total shares held
- 48.13M
- Total value held
- $789.24M
- Institutional holders
- 180
- Unknown6.51M
- Unknown6.10M
- Unknown5.96M
- Unknown2.35M
- Unknown1.92M
- Unknown1.58M
- Unknown1.47M
- Unknown1.20M
- Unknown1.08M
- Unknown1.04M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum
Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.
Analyst Pieces Highlight BioLife Solutions' Customer Retention, Momentum. Two analyst pieces this week focused on BioLife Solutions. Diamond Hill pointed to the company's high switching costs, suggesting customers face barriers to moving to competitors, which can support steady revenue. ChartMill separately noted the stock shows strong growth momentum along with a potential breakout setup. The stock is trading near the lower end of its 52-week range, while analysts maintain an average price target around $31, well above current levels.